Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.
about
Reproducibility over a 1-month period of 1H-MR spectroscopic imaging NAA/Cr ratios in clinically stable multiple sclerosis patientsOutcome Measures in Clinical Trials for Multiple Sclerosis.Several options for antiviral treatment trials in multiple sclerosis--but which targets should be selected?Interferon in relapsing-remitting multiple sclerosis.Comparative efficacy of switching to natalizumab in active multiple sclerosis.Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial.Longitudinal changes in self-reported walking ability in multiple sclerosisPredictors of disability worsening in clinically isolated syndrome.A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple SclerosisThe pathogenesis of multiple sclerosis: is it really a primary inflammatory process?Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.Alemtuzumab improves preexisting disability in active relapsing-remitting MS patientsInvestigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study.Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy.Towards a european network for multiple sclerosis trials (ENMST).Natural, innate improvements in multiple sclerosis disability.Defining reliable disability outcomes in multiple sclerosis.Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon β: Implications for clinical trialsThe natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease
P2860
Q24657825-0DF3572C-9E6A-4329-B105-502668CB8E99Q31160866-3BBE4CBD-C952-42FE-AAD1-A358DC6DE7EDQ34181885-113FEE6E-F26C-45A4-B738-C97B77AFE54EQ34424659-933F02AD-6597-4AA3-93A0-2E10960BB055Q35469575-18F4C563-3565-4EF6-A5D1-A66154447BA9Q35475689-233940C1-E17A-461E-9ECF-B8DB8089EF5AQ35560776-DEB66F5D-D2EF-43D4-93B2-216E4A566EF9Q35619185-DDD522CB-33C6-441D-83CC-F4C5DDDE01A2Q35651621-D000274E-C97C-4F86-B51E-5583CDA7C877Q35820295-239C029F-93E9-4385-8ADB-D27D46DAE076Q35846504-7D70C2C9-CAB0-4D44-8726-F9EAD25F57DAQ36839629-D2237966-C169-419C-83BF-BE8B84A42FC8Q38636586-53B14D2F-7D5A-49C3-B4B3-73D0DDD3E521Q40412270-821566F8-0258-47E8-A02C-98F56E93AAA1Q45108872-882FAFEF-E862-4972-8DEB-CFD93EBFCA4EQ46609780-4AE3CD68-A00D-4736-A211-BBEB7E1CB758Q47244682-3A0C4009-73A1-4E47-811E-759E2F155C79Q47332049-7847CED8-732A-415D-B48D-9A4CDE0DDA8AQ51187507-A7827940-AF29-4192-8C7A-6CF264ED8CB4Q52149517-F76F6AEB-43B0-4C96-8F66-BAC1B9C19FAEQ57602043-3D7E910A-A09F-499B-A14D-DB9B61DC7FBEQ57912352-FF295C52-4029-443E-A763-4F8A7CC760BD
P2860
Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Disability outcome measures in ...... ase course in placebo cohorts.
@ast
Disability outcome measures in ...... ase course in placebo cohorts.
@en
type
label
Disability outcome measures in ...... ase course in placebo cohorts.
@ast
Disability outcome measures in ...... ase course in placebo cohorts.
@en
prefLabel
Disability outcome measures in ...... ase course in placebo cohorts.
@ast
Disability outcome measures in ...... ase course in placebo cohorts.
@en
P2860
P921
P356
P1476
Disability outcome measures in ...... ase course in placebo cohorts.
@en
P2093
P2860
P304
P356
10.1136/JNNP.68.4.450
P407
P577
2000-04-01T00:00:00Z